Design Highlights
- The Inflation Reduction Act allows Medicare to negotiate prices for high-cost drugs, significantly reducing out-of-pocket expenses for seniors.
- Seniors are projected to save $1.5 billion annually starting in 2026 due to these negotiated prices on select medications.
- Price reductions for drugs like Eliquis and Xarelto will let seniors keep hundreds more each year in savings.
- The policy includes a refund rule, ensuring drug prices do not exceed inflation, further protecting seniors’ finances.
- Total potential savings from these reforms could reach $170 billion, easing medication costs for millions of older Americans.
Medicare is shaking things up. Thanks to the Inflation Reduction Act of 2022, the days of exorbitant drug prices for seniors may finally be numbered. For the first time, Medicare can directly negotiate prices for high-cost drugs that don’t have any generic or biosimilar alternatives. This is a game-changer, folks. The Centers for Medicare & Medicaid Services (CMS) is now in charge of this voluntary negotiation process, and it’s already making waves.
The first batch of negotiated prices will kick in on January 1, 2026. Mark your calendars. Among the drugs getting slashed is Eliquis, a blood thinner that will drop from a jaw-dropping $521 to just $231 for a 30-day supply. Xarelto? It’s going from $517 to $197. And if you’re diabetic, prepare for a surprise: Januvia will go from $527 to $113. These are not minor reductions; they’re like finding a hidden stash of cash in your couch cushions.
But wait, there’s more! The second round of negotiations is about to roll out in 2027, featuring 15 more drugs, including the popular GLP-1 diabetes and obesity treatments, Ozempic and Wegovy. The expected savings? A whopping $685 million in annual out-of-pocket expenses for beneficiaries. That’s a serious chunk of change for those counting every penny. In total, the 15 drugs selected for negotiation are projected to account for $42.5 billion in Medicare spending.
Seniors can breathe a little easier, with projections showing they’ll save $1.5 billion annually starting in 2026. The entire Medicare program is expected to save about $6 billion a year just from the first round of negotiations. That’s right, a collective sigh of relief echoing through waiting rooms across the country. Nearly one in seven older Americans who struggle to afford medications will feel a sense of relief. Who knew getting older could come with a little less financial burden? Negotiations are set to expand in subsequent years, bringing even more savings.
But it doesn’t stop there. Drugmakers now have to refund Medicare if they hike prices beyond inflation rates. This is a “no more funny business” policy, projected to save $70 billion over the next decade for over 1,000 drugs. Already demonstrating the power of cost relief, Medicare’s $35 insulin cap introduced in 2023 reduced financial hardship related to insulin costs by 34% among Part D beneficiaries. The total savings could reach $170 billion. Talk about a win-win!
